Paolo Tarantino: Looking forward to presenting this analysis of T-DXd in 1500 patients with MBC

Paolo Tarantino shared a post by Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, on X/Twitter:

“Looking forward to presenting this analysis conducted in collaboration with Yale University, where we look at outcomes with T-DXd in 1500 patients with MBC, analyzed by HER2 status (positive, low, 0), HR status, line of treatment and prior SG. Thanks for the shoutout Yakup Ergün!”

Quoting Yakup Ergün’s post:

“Real-world data from the largest dataset to date on the efficacy of T-DXd in mBC.

Of course, it will be presented by the master of HER-Low and ADCs, Paolo Tarantino.

You should definitely take a look at this study. There is very valuable data on the HR situation and the potential positioning of HER2-Zero.

Abstract #1077.”

Source: Paolo Tarantino/X and Yakup Ergün/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.